These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 10500570)

  • 21. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
    Mycophenolate Mofetil Acute Renal Rejection Study Group
    Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug monitoring of mycophenolic acid in the early period after renal transplantation.
    Krumme B; Wollenberg K; Kirste G; Schollmeyer P
    Transplant Proc; 1998 Aug; 30(5):1773-4. PubMed ID: 9723276
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation.
    Klupp J; Glanemann M; Bechstein WO; Platz KP; Langrehr JM; Keck H; Settmacher U; Radtke C; Neuhaus R; Neuhaus P
    Transplant Proc; 1999; 31(1-2):1113-4. PubMed ID: 10083497
    [No Abstract]   [Full Text] [Related]  

  • 25. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
    Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
    Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
    [No Abstract]   [Full Text] [Related]  

  • 26. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract]   [Full Text] [Related]  

  • 27. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Marcas LI; Manresa JM; Masramón J
    Transplant Proc; 1998 Aug; 30(5):2226-7. PubMed ID: 9723449
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparison of the safety and efficacy of mycophenolate mofetil, prednisolone and cyclosporine and conventional cyclosporine and prednisolone in kidney transplantation.
    Kim HC; Park SB; Kim HT; Cho WH; Park CH
    Transplant Proc; 2000 Nov; 32(7):1751-2. PubMed ID: 11119919
    [No Abstract]   [Full Text] [Related]  

  • 29. Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation.
    Boggi U; Vistoli F; Coppelli A; Marchetti P; Rizzo G; Mosca F
    Transplant Proc; 2001; 33(7-8):3201-2. PubMed ID: 11750373
    [No Abstract]   [Full Text] [Related]  

  • 30. Postmarketing evaluation of mycophenolate mofetil-based triple therapy immunosuppression compared with a conventional azathioprine-based regimen reveals enhanced efficacy and early pharmacoeconomic benefit after renal transplantation.
    Wüthrich RP; Weinreich T; Schwarzkopf AK; Candinas D; Binswanger U
    Transplant Proc; 1998 Dec; 30(8):4096-7. PubMed ID: 9865310
    [No Abstract]   [Full Text] [Related]  

  • 31. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
    Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
    [No Abstract]   [Full Text] [Related]  

  • 32. Treatment of chronic rejection in renal transplantation by mycophenolate mofetil (MMF): a preliminary report of six-month experience.
    Jirasiritham S; Sumethkul V; Mavichak V; Jirasiritham S; Chiewsilp P; Leenanupunth C; Kochakarn W
    Transplant Proc; 1998 Nov; 30(7):3576-7. PubMed ID: 9838566
    [No Abstract]   [Full Text] [Related]  

  • 33. Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic.
    Pirsch JD
    Transplant Proc; 1998 Aug; 30(5):2223-5. PubMed ID: 9723448
    [No Abstract]   [Full Text] [Related]  

  • 34. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.
    Gonwa T; Johnson C; Ahsan N; Alfrey EJ; Halloran P; Stegall M; Hardy M; Metzger R; Shield C; Rocher L; Scandling J; Sorensen J; Mulloy L; Light J; Corwin C; Danovitch G; Wachs M; VanVeldhuisen P; Leonhardt M; Fitzsimmons WE
    Transplantation; 2003 Jun; 75(12):2048-53. PubMed ID: 12829910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppression using tacrolimus/mycophenolate versus neoral/mycophenolate following kidney transplantation: a single-center experience.
    Urbizu JM; Amenabar JJ; Gomez-Ullate P; Zarraga S; Lampreabe I
    Transplant Proc; 2002 Feb; 34(1):87-8. PubMed ID: 11959197
    [No Abstract]   [Full Text] [Related]  

  • 36. Steroid withdrawal in renal transplant recipients.
    Oppenheimer F
    Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
    [No Abstract]   [Full Text] [Related]  

  • 37. Selective CellCept therapy in high-risk renal transplant recipients.
    Isenberg A; Singh TP; Shen GK; Freed BM; Conti DJ
    Transplant Proc; 1998 Jun; 30(4):1188-9. PubMed ID: 9636480
    [No Abstract]   [Full Text] [Related]  

  • 38. A one-center experience with a short course of mycophenolic acid.
    Stephan A; Barbari A; Kamel G; Aoun S; Masri MA
    Transplant Proc; 1999 Dec; 31(8):3289-90. PubMed ID: 10616479
    [No Abstract]   [Full Text] [Related]  

  • 39. Rates of acute rejection by recipient race and type of calcineurin inhibitor with mycophenolate mofetil.
    Mange KC; Bloom RD
    Transplant Proc; 2002 Dec; 34(8):3119-21. PubMed ID: 12493393
    [No Abstract]   [Full Text] [Related]  

  • 40. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.